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Abstract
We have identified the zinc-finger transcription factor Kruppel-like factor 4 (Klf4) among the transcription factors that are
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shorter disease-free survival of subsets of breast cancer patients. Yet, reduced expression of Klf4 also induces apoptosis in
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expression profiling reveals direct Klf4 target genes, including E-cadherin (Cdh1), N-cadherin (Cdh2), vimentin (Vim), b-
catenin (Ctnnb1), VEGF-A (Vegfa), endothelin-1 (Edn1) and Jnk1 (Mapk8). Thereby, Klf4 acts as a transcriptional activator of
epithelial genes and as a repressor of mesenchymal genes. Specifically, increased expression of Jnk1 (Mapk8) upon down-
regulation of its transcriptional repressor Klf4 is required for EMT cell migration and for the induction of apoptosis. The data
demonstrate a central role of Klf4 in the maintenance of epithelial cell differentiation and the prevention of EMT and
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Introduction
Epithelial to mesenchymal transition (EMT) involves the loss of
epithelial-cell markers and gain of mesenchymal-cell markers at
the invasive front of various solid tumors and constitutes a central
step during carcinogenesis [1,2,3,4,5]. Acquiring mesenchymal
properties liberates these cells from the primary tumor and allows
them to invade neighboring tissue, to enter the circulation and to
colonize distant organs. The dramatic changes in cell morphology
and behavior during the process of EMT and metastasis are
accompanied by substantial changes in gene expression. Recently,
a number of transcription factors have been identified that play
critical roles in the initiation and execution of EMT and in the
metastatic process, including Snail1 (Snail), Snail2 (Slug), Zeb1
(dEF1), Zeb2 (Sip1), E47, Twist, goosecoid, FoxC2, Dlx2, RBPjk,
Yap/Taz, Sox9 and NFkB [6,7,8]. However, the activities of these
transcriptional regulators do not explain the full range of changes
in gene expression during the multistage process of EMT,
indicating that additional transcription factors with master control
functions must exist.
We have previously established a list of genes that change in
their expression during the consecutive morphological states of
TGFb-induced EMT in normal mammary epithelial cells
(NMuMG) [9]. This analysis identified Kruppel-like factor 4
(Klf4) as a transcription factor that is reduced in its expression
during TGFb-induced EMT. Klf4 is a zinc-finger transcription
factor which is usually expressed in growth-arrested cells and in
differentiated cells of the colon, small intestine, testis and lung
[10]. Notably, the expression of Klf4 is down-regulated in several
different cancer types [11,12,13,14,15,16,17]. Yet, Klf4 has also
been found highly expressed in dysplastic epithelium, in breast
cancers and in squamous cell carcinoma of the oropharynx [18].
Moreover, Klf4 has been shown to act as an oncogene cooperating
with c-Myc in the transformation of cells, and the inducible
expression of Klf4 in mice is sufficient to provoke skin dysplasia
and squamous cell carcinoma [19,20]. In contrast, database-
mining analysis reveals a correlation between low Klf4 expression
and an increased incidence of malignant breast carcinoma [21].
Accordingly, Klf4 exhibits a dual function as a transcriptional
activator as well as a repressor at the promoter of various genes in
a context-dependent manner [22]. For example, Klf4 executes its
oncogenic activity by directly binding to and repressing the p53
gene promoter. In contrast, it acts as a tumor suppressor by
binding to and activating the promoter of the p21 cell cycle
inhibitor gene [22]. Interestingly, together with Oct4, Sox2 and c-
Myc, Klf4 is a pivotal factor in the generation of induced
pluripotent cells [23] and is required for the epigenetic
reprogramming of a somatic genome [24]. Klf4 knockout mice
die shortly after birth due to the loss of skin barrier function as a
result of the defective differentiation of the cornified envelope [25].
Similarly, Klf4 is required to maintain the cell morphology of
mammary epithelial cells: while its loss induces EMT-like
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morphological changes, forced expression of Klf4 in invasive
breast cancer cells induces epithelial differentiation by directly
repressing the expression of Snail1, a potent repressor of E-
cadherin gene expression, and by directly binding to the E-
cadherin promoter and up-regulating E-cadherin expression [26].
However, other direct Klf4 target genes and the molecular
mechanisms underlying Klf4’s functional contribution to EMT
and metastasis have remained elusive.
Here, we show that Klf4 is essential for the maintenance of
epithelial differentiation and that the loss of its function is required
and in part sufficient to induce EMT and metastasis. A
combinatorial approach of gene expression profiling and chroma-
tin immunoprecipitation/deep sequencing (ChIP-Seq) analysis
revealed many key EMT genes as direct transcriptional targets of
Klf4, including N-cadherin (Cdh2), vimentin (Vim), b-catenin
(Ctnnb1), VEGF-A (Vegfa), endothelin-1 (Edn1) and Jnk1 (Mapk8).
Of these, Jnk1 plays a central role in mediating Klf4-controlled
EMT, migration and apoptosis.
Results
Identification of Klf4 as a Transcriptional Regulator of
EMT
We have utilized an established model of EMT, the untrans-
formed normal murine mammary gland cell line NMuMG, to
decipher the gene regulatory mechanisms underlying EMT [9].
NMuMG cells undergo progressive EMT upon TGFb treatment
and acquire a complete mesenchymal morphology by more than
10 days of TGFb treatment (Figure S1A). Genome-wide gene
expression analysis of NMuMG cells during TGFb-induced EMT
identified differentially expressed genes at the respective stages.
Amongst a large number of genes changing in their expression
during EMT, Klf4 mRNA and protein levels were found down-
regulated already at day 1 of TGFb treatment (Figure 1A; Figure
S1B). Decreased expression of Klf4 during TGFb-induced EMT
was also confirmed in the murine breast cancer cell line Py2T,
which has been established from a breast tumor of MMTV-PyMT
transgenic mice [27], as well as in EpRas cells (Figure 1B–C,
Figure S1B). Similar to NMuMG cells, both of these cell types
undergo EMT upon TGFb treatment. Klf4 expression was also
found reduced in human breast cancer cell lines, such as in
SKBR3 upon EGF-induced EMT and in MCF7 cells which
undergo EMT upon stable depletion of E-cadherin (Figure 1D, E)
[9]. Notably, the levels of Klf4 mRNA were not reduced either
upon TGFb-treatment in NMuMG cells stably depleted for
Smad4 (shSmad4 [28]; Figure S1C) or upon treatment with
TGFbR inhibitor in NMuMG and Py2T cells in the absence and
presence of TGFb (Figure S1D, E), suggesting that canonical,
Smad4-dependent TGFb signaling represses Klf4 expression, as
observed during TGFb-induced EMT in NMuMG cells.
Klf4 Maintains the Epithelial Differentiation Status
We next directly assessed the functional contribution of Klf4 to
EMT. Transfection of a pool of two siRNAs against Klf4 (siKlf4)
efficiently ablated Klf4 expression in NMuMG cells (Figure S2A).
In the absence of TGFb, Klf4 ablation induced modest changes in
cell morphology with a slight increase in cell size accompanied
with cell flattening, a partial loss of cell-cell adhesion and an
increase in filopodia formation (Figure 2A, left panel). Immuno-
blotting and immunofluorescence microscopy analysis revealed an
increase in the expression of mesenchymal markers, such as N-
cadherin and vimentin, in siKlf4 cells as compared to control
siRNA-transfected cells (siControl; Figure 2B, C, left panels). In
addition, focal adhesion and actin stress fiber formation were
substantially increased, as visualized by staining with paxillin
antibody and fluorescently labeled phalloidin, respectively
(Figure 2C). Conversely, the epithelial adherens junction protein
E-cadherin was moderately reduced and displaced from the
membrane junctions in siKlf4 as compared to siControl cells,
while no change was observed with the tight junction protein ZO-
1 (Figure 2C). Consistent with these findings, depletion of Klf4
expression in the presence of TGFb markedly accelerated the
EMT process; siKlf4 cells became more spindle-shaped and
fibroblast-like as early as 2 days of TGFb treatment, resembling
siControl cells treated with TGFb beyond 10 days (Figure 2A,
middle and right panels). Immunoblotting and immunofluores-
cence analysis at day 2 of TGFb treatment revealed that the
morphological changes in siKlf4 cells were accompanied by
increased expression of the mesenchymal markers vimentin and
N-cadherin and an accelerated loss of the epithelial markers ZO-1
and E-cadherin from the cell membranes (Figure 2B, C). Notably,
ablation of Klf4 expression in NMuMG cells that had been
previously treated with TGFb for 15 days still induced a more
mesenchymal and spindle-like cell morphology as compared to
siControl cells, indicating that Klf4 is not only inhibitory to the
initiation but also to the maintenance of EMT (Figure 2A, right
panel). The acceleration of EMT upon depletion of Klf4 function
was further confirmed in Py2T murine breast cancer cells (Figure
S2A–D). Together, these results demonstrate a critical role of Klf4
in maintaining epithelial morphology and in preventing EMT.
Klf4 Prevents Cell Migration and Promotes Cell Survival
during EMT
Since cell migration constitutes a key feature in forming
metastasis via EMT, we assessed the migratory capacity of Klf4
knockdown cells. Scratch wound closure assays revealed that
siKlf4 NMuMG cells migrated significantly faster than siControl
cells even in the absence of TGFb (Figure 3A and. Figure S3A).
Scratch wound closure was also moderately accelerated in
NMuMG cells stably depleted for Klf4 expression (shKlf4) by
using three different shRNAs as compared to shControl cells
(Figure 3B and Figure S3B). Moreover, transwell migration assays
with shKlf4 cells revealed a significantly higher chemotactic
migration as compared to shControl cells both in the absence and
presence of TGFb (Figure 3C and D, respectively). Comparable
results were observed in Py2T cells depleted of Klf4 (Figure S3C).
Together, these results indicate that Klf4 represses cell migration.
Klf4 has been shown to inhibit proliferation and promote
differentiation of skin and colonic epithelium [14,25]. Thus, we
next investigated whether Klf4 depletion affected NMuMG cell
proliferation and survival during TGFb-induced EMT. Surpris-
ingly, depletion of Klf4 expression led to a decrease in NMuMG
cell number after treatment with TGFb, an effect that was not
observed in the absence of TGFb (Figure 3E). Propidium iodide
staining and flow cytometry analysis revealed a significant G0/G1
cell cycle arrest in siKlf4 cells as compared to siControl cells in the
presence of TGFb (Figure 3F). In addition, Annexin V staining
showed an increase in apoptosis in siKlf4-transfected cells after
treatment with TGFb as compared to siControl-transfected cells
(Figure 3G). Hence, the TGFb-sensitive, decreased growth of
siKlf4 cells depended on both decreased proliferation and
increased apoptosis. Unlike NMuMG cells, Py2T cells did not
undergo apoptosis during TGFb-induced EMT. However, apop-
tosis in Klf4-depleted Py2T cells was significantly higher as
compared to siControl Py2T cells, although not as substantial as
observed with NMuMG cells (Figure S3D), and siKlf4 Py2T cells
did not arrest in G0/G1 during TGFb treatment (Figure S3E).
Together, these results reveal an inhibitory role of Klf4 in cell
Klf4 Regulates EMT
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migration as well as a supportive role in cell proliferation and cell
survival during TGFb-induced EMT, with varying degrees
depending on the cells’ transformation status.
Ectopic Expression of Klf4 Prevents EMT
We next assessed whether the forced expression of Klf4 was
sufficient to prevent EMT. We generated NMuMG cells
expressing a Myc-Klf4-estrogen receptor (ERTM) fusion protein,
where Klf4-ERTM translocated to the nucleus upon treatment with
the Tamoxifen derivative, 4-hydoxy-Tamoxifen (4-OHT [19];
Figure 4A). Upon treatment of the cells with 4-OHT, morpho-
logical changes in the presence and absence of TGFb were
determined. Interestingly, despite the presence of TGFb, Klf4-
activated cells largely retained their epithelial phenotype (+OHT),
also manifested by the high expression of the epithelial markers E-
cadherin and ZO-1 and a failure to induce expression of
mesenchymal markers, such as N-cadherin, compared to con-
trol-treated cells (2OHT; Figure 4B and C). Klf4 also inhibited
cell migration in scratch wound closure and transwell migration
assays (Figure 4D and 4E). In addition, Klf4 activation also
blocked TGFb-induced apoptosis (Figure 4F) and, as a result, cell
numbers were increased in growth curves as compared to Klf4-
ERTM-transfected NMuMG cells in the absence of 4-OHT
(Figure 4G). Comparable results were obtained with Klf4-ERTM-
transfected Py2T cells, where the 4-OHT-mediated activation of
Klf4 attenuated TGFb-induced EMT (Figure S4A and B). These
results suggested that Klf4 elicits a transcriptional program that is
critical in the maintenance of the epithelial phenotype and the
prevention of EMT.
Klf4 Blocks Malignant Tumor Progression and Metastasis
We next assessed whether decreased expression of Klf4
correlated with the ability of breast cancer to progress and
metastasize in patients. A positive and significant correlation of
decreased Klf4 expression with tumor grade has been previously
reported [21]. Our analysis of the Uppsala database of breast
Figure 1. Klf4 expression is down-regulated during EMT. (A–C) Klf4 mRNA levels were quantified by quantitative RT-PCR during TGFb-
induced EMT in NMuMG cells (A), Py2T cells (B) and EpRas cells (C). (D) Klf4 levels were quantified by quantitative RT-PCR in SKBR3 cells after EGF-
induced EMT. SKBR3 cells were treated with 25 ng/ml EGF for 4 days. Shown are the fold-changes as compared to day 0 (no EGF). (E) Quantitative RT-
PCR analysis of Klf4 mRNA levels in MCF7 cells either stably expressing a control shRNA (shControl) or an shRNA against E-cadherin (shEcad).
Statistical values were calculated using a paired, two-tailed t-test and experiments were performed at least three times. * = p#0.05; ** = p#0.01;
*** = p#0.001.
doi:10.1371/journal.pone.0057329.g001
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Figure 2. Klf4 maintains epithelial morphology and prevents EMT. (A) NMuMG cells were transfected with either control siRNA (siControl) or
Klf4-specific siRNA (siKlf4) in the absence as well as in the presence of TGFb for 2 or 15 days, as indicated. The levels of Klf4 mRNA were determined by
quantitative RT-PCR and the morphology of the cells evaluated by phase contrast microscopy. Filopodia and membrane protrusions are marked with
closed arrowheads. Size bar, 100 mm. (B) Immunoblotting analysis of the expression of the epithelial marker ZO-1 and the mesenchymal markers N-
cadherin and Vimentin during TGFb-induced EMT in control NMuMG cells (siControl) and Klf4 depleted cells (siKlf4). (C) Immunofluorescence
microscopy analysis of changes in the localization and expression levels of EMT markers during EMT. NMuMG cells transfected with either control
siRNA (siControl) or with siRNA against Klf4 (siKlf4) were left untreated or treated with TGFb for 2 days and stained with antibodies against the
epithelial markers E-cadherin and ZO-1, against the mesenchymal markers N-cadherin and vimentin, against paxillin to detect focal adhesion plaques,
and with phalloidin to visualize the actin cytoskeleton. Size bar, 50 mm. Statistical values were calculated by using a paired, two-tailed t-test and
experiments were performed at least three times. *** = p#0.001.
doi:10.1371/journal.pone.0057329.g002
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cancer [29,30] revealed that low Klf4 expression correlated with
shorter disease-free survival. This correlation was highly significant
with breast cancers expressing estrogen receptor (ER+) or
exhibiting lymph node metastasis (LN+) (Figure 5A–C) and was
lower but still significant in breast cancers with ER2 and LN2
status (Figure S5A and B). Moreover, in the TRANSBIG breast
cancer database [31], low Klf4 expression levels correlated with
shorter relapse-free survival of ER+ breast cancer patients
(Figure 5D).
These observations led us to investigate whether the forced
expression of Klf4 in Py2T cells could affect the ability of these
cells to form tumors and undergo metastasis upon transplantation
into mice. We generated inducible Klf4-expressing Py2T cells
(Klf4-ERTM) that also expressed firefly luciferase and showed high
Klf4 expression and nuclear localization in the presence of 4-OHT
(Figure S5C). These cells were then orthotopically implanted into
the mammary fat pad of nude mice, and tumor growth and
metastasis in lung and liver were quantified in mice treated or not
with Tamoxifen in the food. Histopathological examination of the
primary tumors revealed an invasive and dedifferentiated pheno-
type in the absence of Tamoxifen and a more differentiated and
less invasive morphology upon Tamoxifen treatment (Figure 5E).
In addition, expression of epithelial marker E-cadherin is retained
at the cell membrane while expression of mesenchymal markers
N-cadherin and fibronectin are decreased after Klf4 induction in
tumor sections (Figure S5D). Similar to the findings in vitro, the
activation of Klf4 in Py2T cells led to significantly decreased rates
of apoptosis in Klf4-activated tumors (Figure 5F), while tumor cell
proliferation was only moderately increased (Figure S5E). As a
consequence, tumor growth and tumor weight were significantly
increased upon activation of Klf4 (Figure 5G), yet decreased
luciferase levels were observed in organs that are known targets of
metastasizing breast cancer cells, such as lung and liver (metastatic
index; Figure 5H; Figure S5F). Together, these results indicate
that Klf4 activity increases primary breast tumor growth but
prevents its metastatic spread.
Klf4 Directly Regulates the Expression of Crucial EMT
Genes
Our observations propose a critical transcriptional role of Klf4
in the regulation of primary tumor growth, EMT and metastasis.
Hence, we set out to identify the genes that are regulated by Klf4.
Genome-wide gene expression profiling between NMuMG cells
either transfected with control siRNA (siControl) or with siRNA
against Klf4 (siKlf4) in the absence and presence of TGFb (2 days)
revealed a number of genes that were significantly up and down-
regulated in response to Klf4 expression. To identify the direct
target genes of Klf4, i.e. the genes whose promoters are directly
bound by Klf4, we performed chromatin immunoprecipitation
using a Klf4-specific antibody in NMuMG cells followed by next
generation sequencing (ChIP-Seq). The list of gene promoters
directly bound by Klf4 was compared to the lists of genes that were
changed in their expression in dependence on Klf4 and that were
regulated during the different stages of TGFb-induced EMT in
NMuMG cells (Figure 6A; Figure S6A-D). This analysis identified
33 direct Klf4 target genes with increased expression during EMT
and 57 direct Klf4 target genes with reduced expression during
EMT (Table S1). Gene ontology analysis revealed that the direct
target genes of Klf4 are mainly active in signaling pathways
regulating EMT, cell adhesion, cell cycle control and angiogenesis
(Table S2). Among the genes, we identified a number of well-
established EMT marker genes, including the epithelial marker
gene E-cadherin (Cdh1), previously shown to be directly activated
by Klf4 [26], and the mesenchymal markers N-cadherin (Cdh2),
vimentin (Vim), b-catenin (Ctnnb1), vascular endothelial growth
factor A (Vegfa) and endothelin-1 (Edn1), all of which are up-
regulated in their expression upon loss of Klf4 function during
EMT. Quantitative real-time RT-PCR showed that expression of
these genes was in fact modulated by Klf4 activity (data not
shown). ChIP followed by quantitative PCR using specific primers
for the particular gene promoters confirmed the direct binding of
Klf4 to the promoters of the N-cadherin (Cdh2), vimentin (Vim) and
b-catenin (Ctnnb1) genes (Figure 6B), and the DNA fragments
bound by Klf4 were found within the promoter regions close to the
transcriptional start sites of these genes (Figure 6C). The genes
encoding for N-cadherin, vimentin and b-catenin were also
confirmed as direct transcriptional targets of Klf4 in Py2T cells
by ChIP-qPCR (Figure S6E). These results indicate that Klf4 is a
transcriptional activator of epithelial genes and a transcriptional
repressor of mesenchymal genes and that its loss represents a
major switch in the initiation of EMT.
Klf4 Prevents EMT by Repressing Jnk1 Expression
Among the various genes identified in the course of our
experiments, Jnk1 (Mapk8) was significantly up-regulated in its
expression at the mRNA and protein level in Klf4-depleted
NMuMG (Figure 7A and B) and Py2T cells (Figure S7A) and
down-regulated in Klf4 over-expressing NMuMG and Py2T cells
(Figure S7B and C). ChIP using Klf4-specific antibody followed by
qPCR revealed that Klf4 directly bound the Jnk1 gene promoter
in NMuMG (Figure 7C) and Py2T cells (Figure S7D). Moreover,
increased AP1 reporter activity after Klf4 depletion in the absence
and presence of TGFb confirmed the repressive role of Klf4 for
Jnk1-mediated signal transduction (Figure 7D).
We next assessed the functional contribution of Jnk1 expression
to EMT. Transient knockdown of Jnk1 using a pool of two siRNA
(siJnk1) led to a significant reduction in Jnk1 expression (Figure
Figure 3. Klf4 inhibits cell migration and promotes cell survival and proliferation during TGFb-induced EMT. (A) siRNA-mediated
ablation of Klf4 results in an increase in NMuMG cell migration even in the absence of TGFb as determined by scratch wound closure assays (see
pictures in Figure S3A). (B) Stable shRNA-mediated depletion in NMuMG cells using three different shRNA sequences specific for Klf4 results in
moderately increased cell migration as determined by scratch wound closure assays (see pictures in Figure S3B). (C) Stable shRNA-mediated
depletion of Klf4 expression in NMuMG cells results in increased cell migration as determined by trans-well migration assays using 20% FBS as a
chemo-attractant in the absence of TGFb. (D) Stable shRNA-mediated depletion of Klf4 expression in NMuMG cells previously treated for 20 days with
TGFb results in increased cell migration as determined by trans-well migration assays using 20% FBS as a chemo-attractant. (E) siRNA-mediated
ablation of Klf4 expression during TGFb treatment of NMuMG cells results in a significant decrease in cell numbers as compared to cells transfected
with control siRNA, while the depletion of Klf4 has no effect on cell number in the absence of TGFb. (F) NMuMG cells transfected with either control
siRNA (siControl) or with siRNA against Klf4 (siKlf4) were treated with TGFb for the days indicated. Cells were stained with propidium iodide (PI), and
the percentages of cells in G0/G1 and S-G2/M phases of the cell cycle were determined by flow cytometry analysis. (G) NMuMG cells transfected with
either control siRNA (siControl) or with siRNA against Klf4 (siKlf4) were treated with TGFb for the days indicated, and the rates of apoptosis were
determined by Annexin-V staining and flow cytometry. Note that in the 15 days experiment, cells were first treated with TGFb for 13 days and then
transfected with siRNA constructs. Statistical values were calculated using an unpaired/paired, two-tailed t-test and experiments were performed at
least three times. * = p#0.05; ** = p#0.01; *** = p#0.001.
doi:10.1371/journal.pone.0057329.g003
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Figure 4. Klf4 prevents EMT and cell migration and supports cell survival during EMT. (A) Immunofluorescence staining of NMuMG cells
stably expressing a Myc-Klf4-ERTM fusion protein using an anti-Myc-tag antibody to visualize the nuclear localization of Klf4 with and without 4-
Klf4 Regulates EMT
PLOS ONE | www.plosone.org 7 February 2013 | Volume 8 | Issue 2 | e57329
S7E). Interestingly, similar to cells over-expressing Klf4, Jnk1
depletion preserved an epithelial differentiation status and lead to
a retention of epithelial morphology even in the presence of TGFb
in NMuMG cells (Figure 7E). Immunoblotting and immunoflu-
orescence analysis revealed that Jnk1-depleted cells maintained the
expression of epithelial markers and failed to induce the expression
of mesenchymal markers during TGFb-induced EMT (Figure 7F,
G). Moreover, TGFb-induced stress fiber formation was also
prevented (Figure 7G). Notably, while siRNA-mediated depletion
of Klf4 induced EMT, cell migration and apoptosis, the depletion
of Jnk1 in the Klf4-knockdown cells largely prevented these
processes (Figure 7H, I; Figure S7F). These experiments demon-
strate a critical role of Klf4 in preventing EMT and apoptosis by
the direct transcriptional repression of the Jnk1 (Mapk8) gene,
which itself is required for EMT, cell migration and TGFb-
induced apoptosis. However, the forced expression of Jnk1 in
NMuMG cells was not sufficient to induce EMT in the absence of
TGFb or a reduced expression of Klf4 (data not shown), indicating
that the loss of Klf4 expression and the changed expression of
other Klf4 target genes are required for EMT to occur.
Discussion
EMT is a multistage process that is essential in early embryonic
development, a program that is hijacked by various pathological
conditions, such as tissue fibrosis and malignant tumor progression
and metastasis. EMT is accompanied by major alterations in cell
morphology, cell-cell and cell-matrix adhesions and in the motile
and invasive capabilities of cells, accomplished by major changes
in gene expression during the acquisition and maintenance of an
EMT. Here, using genome-wide gene expression profiling, we
have identified Klf4 as one critical regulator of EMT. Notably,
Klf4 is a major repressor of EMT: its expression prevents EMT
and maintains an epithelial morphology of mammary epithelial
cells and of breast cancer cells, while its ablation results in a loss of
epithelial morphology and in a partial induction and acceleration
of EMT. In addition, we find that Klf4 also supports cell
proliferation and survival while inhibiting cell migration. This
notion contrasts previous studies showing that Klf4 inhibits cell
proliferation in a colon cancer cell line and that it acts as a pro-
migratory factor in the MCF7 and MDA-MB-231 human breast
cancer cell lines [32,33]. These differences could be the result of
higher levels of Klf4 in breast cancer cell lines. However, in
contrast to the findings in the above study, we found downreg-
ulation of Klf4 in MCF7 cells after E-cadherin depletion and a
recent report also demonstrated a migration and invasion-
repressive role of Klf4 in MDA-MB-231 cells [26].
Klf4 is known for its dual role as a transcriptional activator and
repressor. Previous studies have suggested that Klf4 is a critical
factor in maintaining the cell morphology of mammary epithelial
cells. It directly represses the expression of Snail1, one of the major
transcriptional repressors of E-cadherin gene expression, and also
directly binds to the E-cadherin gene promoter and up-regulates
E-cadherin expression [26,34]. Our combined genome-wide gene
expression profiling and ChIP-Seq data analysis has also revealed
Klf4 binding to the Snail1 (Snai1) and E-cadherin (Cdh1) gene
promoters. Indeed, Snai1 expression appears regulated by Klf4, as
it is significantly up-regulated upon depletion of Klf4 in the
absence of TGFb. However, in the presence of TGFb Snail1
expression is reduced in Klf4 knockdown cells (Figure S8A),
suggesting that Klf4-mediated regulation of the Snai1 gene is a
complex process and besides Klf4 involves other transcription
factors that repress or activate Snai1 transcription. On the other
hand, Klf4 ablation leads to an up-regulation of Twist1 expression
in the presence of TGFb that may act as the main driver of EMT
in the mesenchymal state (Figure S8B). Reduced Klf4 expression
did not alter the expression of Snail2, Zeb1, Zeb2 and other major
EMT regulators (data not shown). Moreover, we identified
additional genes that are directly induced or repressed in their
expression by Klf4. Notably, a number of mesenchymal genes,
such as N-cadherin (Cdh2), vimentin (Vim), and b-catenin (Ctnnb1),
are direct targets of Klf4 transcriptional repression. Together, the
data proposes a model in which Klf4 maintains epithelial
morphology by inducing the expression of epithelial-specific genes
and by repressing mesenchymal genes (Figure S9). Upon loss of
Klf4 function during EMT, epithelial gene expression is lost, and
mesenchymal genes are activated. A similar function of Klf4 was
observed during reprogramming of fibroblasts into induced
pluripotent stem (iPS) cells, where Klf4 as one of the key
reprogramming factors activates Cdh1 expression, resulting in
mesenchymal-epithelial transition (MET) and reprogramming of
fibroblasts [35]. These observations further illustrate that Klf4-
mediated transcription control is not only important for main-
taining the identity of epithelial cells but also in its establishment.
Moreover, Klf4 also represses several genes involved in angiogen-
esis, including VEGF-A (Vegfa) and Endothelin-1 (Edn1). These
results suggest that the loss of Klf4 expression during EMT is a
critical event in promoting tumor angiogenesis, malignant tumor
progression and metastasis.
We further show that one of the transcriptionally repressed
target genes of Klf4 is Jnk1 (Mapk8); upon loss of Klf4 during
TGFb-induced EMT, Jnk1 is induced in its expression and exerts
a critical function in the execution of EMT and cell migration but
also in the induction of apoptosis. Jnk1 is a member of the
mitogen-activated protein kinases (Mapk) family of serine-threo-
hydroxy-Tamoxifen (6 OHT) treatment in the absence as well as in the presence of TGFb for 2 days. Size bar, 50 mm. (B) Induction of Klf4
transcriptional activity by treatment of Myc-Klf4-ERTM-expressing NMuMG cells treated with 4-OHT (+OHT) results in a repression of the
morphological changes occurring during TGFb-induced EMT in control-treated cells (2OHT). Shown are phase contrast images of Myc-Klf4-ERTM
expressing NMuMG cells treated with TGFb for 0, 1, 4 and 7 days in the absence or presence of 4-OHT. Size bar, 100 mm. (C) Immunoblotting analysis
of the expression of the epithelial markers E-cadherin and ZO-1 and the mesenchymal marker N-cadherin during TGFb-induced EMT in control
NMuMG cells and in Myc-Klf4-ERTM-expressing NMuMG cells in which Klf4 transcriptional activity has been induced (+OHT) or not (2OHT). Activation
of Klf4 in Klf4-ER (+OHT) cells results in the maintenance of the expression of epithelial markers and the failure to express mesenchymal markers.
Immunoblotting for actin was used as loading control. (D) Activation of Klf4 by treatment of Myc-Klf4-ERTM-expressing NMuMG cells with 4-OHT
(+OHT) results in reduced cell migration in scratch wound closure assays as compared to control-treated Myc-Klf4-ERTM-expressing NMuMG cells
(2OHT). Cells have been treated with TGFb for 15 days prior to the migration assays. (E) Activation of Klf4 (+OHT) represses cell migration in trans-
well migration assays by using 20% FBS as a chemoattractant for 20 hours in 15 days TGFb-treated Myc-Klf4-ERTM-expressing NMuMG cells. (F)
Induction of Klf4 transcriptional activity by treatment of Myc-Klf4-ERTM-expressing NMuMG cells with 4-OHT (+OHT) results in reduced apoptosis as
compared to Myc-Klf4-ERTM-expressing NMuMG cells in the absence of 4-OHT (2OHT). Apoptosis was quantified by Annexin-V staining and flow
cytometry. (G) Activation of Klf4 by treatment of Myc-Klf4-ERTM-expressing NMuMG cells with 4-OHT (+OHT) results in a significant increase in cell
numbers as compared to the same cells cultured in the absence of 4-OHT (2OHT). Statistical values were calculated using an unpaired/paired, two-
tailed t-test and experiments were performed at least three times. ** = p#0.01; *** = p#0.001.
doi:10.1371/journal.pone.0057329.g004
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Figure 5. High Klf4 expression correlates with good survival prognosis in patients and prevents metastasis in experimental models.
(A–C) Kaplan-Meier survival analysis reveals a significant correlation between low Klf4 expression levels and poor overall disease-free survival (A) by
correlating high or low Klf4 expression levels with all patient samples (Uppsala database). Correlation of Klf4 expression levels with disease-free
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nine protein kinases that participate in various signaling pathways
and are critical for cellular responses to extracellular stimuli. Jnk1
is activated primarily by cytokines and cellular stress, such as UV
light, which leads to Jnk1 phosphorylation at serine-63 and serine-
73 residues [36]. Such activation of Jnk is required for UV-
induced apoptosis in primary murine embryonic fibroblasts and to
maintain the mitochondrial apoptosis signaling pathway [37]. Jnk1
and their target transcription factor AP1 (Jun/Fos) have also been
previously implicated in EMT [38,39,40]. In line with these
observations, Jnk1 can phosphorylate paxillin, a focal adhesion
adaptor, required for the formation of focal adhesion plaques and
for efficient cell migration [41]. Here, we show that Jnk1 exerts a
critical role in EMT, cell migration and in the induction of
apoptosis upon loss of its direct transcriptional repressor Klf4.
Recent reports have demonstrated that Jnk1, Jnk2 or composite
Jnk1 and 2 deficiencies promote primary tumor formation in
various mouse models of breast cancer [42,43,44] These data are
consistent with our findings that Klf4, by repressing Jnk1 gene
expression, prevents apoptosis and promotes primary tumor
growth while inhibiting metastasis formation.
Thus, our experimental data in cultured cells and in mouse
transplantation models highlight Klf4’s function as a suppressor of
malignant breast carcinogenesis. Moreover, we find that high Klf4
expression correlates with increased disease-free survival in
patients, for example in the Uppsala breast cancer database
[29,30] and in the TRANSBIG breast cancer database [31].
However, our experimental results also reveal that Klf4 not only
prevents lung and liver metastasis but also provides a survival
advantage to cells, thus leading to increased primary tumor
growth. These data are in contrast to findings reported by Yori
et al. showing that the forced expression of Klf4 in 4T1 cells
murine breast cancer cells not only reduces lung and liver
metastasis but also primary tumor growth [34]. However, in
another study these authors also observe a role of Klf4 in
promoting cell survival [26], and Yu et al. have previously
reported that silencing of Klf4 in MDA-MB-231 cells represses
primary tumor growth [33].
Together, the data reported herein reveal fundamental princi-
ples of how transcription factors like Klf4 regulate cell-fate changes
by directly modulating the transcription of underlying genes. In
addition to demonstrating that Smad4-dependent TGFb signaling
represses Klf4 expression, our data also suggest that Wnt and
EGFR signaling may also contribute to Klf4 transcriptional
regulation, as treatment of NMuMG and Py2T cells with the Wnt
activator LiCl or with an inhibitor of EGFR signaling (EGFRi)
leads to up-regulation of Klf4 in the absence as well as in the
presence of TGFb (Figure S1C and D). However, the detailed
molecular mechanisms of this regulation during EMT remain to
be delineated. Finally, the critical functions of Klf4 in the
maintenance of epithelial differentiation and in the prevention of
EMT and metastasis make Klf4 and its transcriptional effectors
attractive targets for the development of novel therapeutic
approaches. Notably, the activities of Jnk1 that are up-regulated
upon loss of Klf4 function may offer a therapeutic avenue to
metastatic disease, a notion that warrants further investigation.
Materials and Methods
Reagents and Drugs
Reagents. PBS (D8537, Sigma-Aldrich), trypsin (T4174,
Sigma-Aldrich), Opti-MEM (11058, Gibco), Glutamine (G7513,
Sigma-Aldrich), Pencillin/streptomycin (P4333, Sigma-Aldrich),
Alexa Fluor-488, 568, 633 (Invitrogen), Polybrene (AL-118,
Sigma-Aldrich), Fugene HD (12998300, Roche), Bradford reagent
(500-0006, Biorad), Protease inhibitor cocktail (P2714, Sigma-
Aldrich).
Drugs: TGFbRi (SB431542; S4317, Sigma); EGFRi (AG1478;
ALX-270-036, Axxora); LiCl (L9650, Sigma).
Cell Lines and Cell Culture
A subclone of NMuMG cells (NMuMG/E9; hereafter
NMuMG) [45] and MCF7 shControl and MCF7-shEcad have
been described before [9]. Py2T cells were isolated from a breast
tumor of an MMTV-PyMT transgenic female mouse in an FVB/
N background [27]. EpRas cells have been obtained from H. Beug
(IMP, Vienna) and SKBR3 cells have been obtained from ATCC.
NMuMG, Py2T and EpRas cells were cultured in DMEM
supplemented with glutamine, penicillin, streptomycin, and 10%
FBS (Sigma) while SKBR3 cells were grown in RPMI-1640
supplemented with glutamine, penicillin, streptomycin and 10%
FBS. NMuMG-shSmad4 and NMuMG-shControl were kindly
provided by P. ten Dijke (LUMC, The Netherlands) [28]. Cells
were cultured in DMEM (D5671, Sigma)/10% FBS (F7524,
Sigma) and treated with 2 ng/ml TGFb (240-B, R&D systems) for
the indicated time points and replaced every 2nd day. For siRNA
transfections, Lipofectamine RNAiMax (11668-019, Invitrogen)
was used according to the manufacturer’s instructions.
Cell Growth
For growth curves, cells were counted as described earlier [8].
For Cell cycle analysis, propidium iodide (PI; P4170, Sigma) was
used according to the manufacturer’s instructions. Stained cells
were analyzed on a FACSCanto II using DIVA software.
Production of Lentivirus for Knockdown Studies and
Retrovirus for Overexpression Studies
Murine Klf4 shRNAs and control shRNA were used for
knockdown studies while Myc-Klf4-ER construct (kindly provided
by Prof. J.M. Ruppert), cloned into the retroviral expression vector
pBabe, was used for overexpression studies. Lentivirus production
survival was further determined after stratifying the patient samples into lymph node-positive (LN+; B) and estrogen receptor-positive (ER+; C) tumor
groups. (D) Kaplan-Meier survival analysis reveals a significant correlation between poor relapse-free survival in ER+ breast cancer patients (TRANSBIG
database) and low Klf4 expression. (E) Myc-Klf4-ERTM and firefly luciferase-expressing Py2T cells were orthotopically transplanted into the mammary
fat pad of immune-compromised Balb/c nude mice. Mice were treated with normal food or with food containing Tamoxifen to induce Klf4
transcriptional activity. Shown are images of histological sections of primary tumors stained with hematoxylin and eosin. Note that Klf4 appears to
repress the invasive morphology of the tumors. Size bar, 100 mm. (F) The percentages of apoptotic cells were quantified by cleaved caspase 3
staining of histological tumor sections described in (E). Activation of Klf4 by Tamoxifen repressed apoptosis in the primary tumors. (G) Primary tumor
volumes were calculated after transplantation of Myc-Klf4-ERTM cells as described in (E) while tumor weights were calculated after sacrificing the
tumor-bearing mice 27 days post-injection. Activation of Klf4 by Tamoxifen promoted tumor growth. (H) Metastatic spread was determined in the
Myc-Klf4-ERTM cells -transplanted mice described in (E) by measuring luciferase activity in extracts of lungs and livers of the transplanted mice.
Luciferase activity levels in the various organs were divided by the primary tumor weights within the same mice to establish the metastatic index, as
shown. Activation of Klf4 by Tamoxifen represses metastatic spread of the transplanted tumor cells. Statistical values for panels F – H were calculated
using an unpaired/paired, two-tailed t-test. * = p#0.05; ** = p#0.01; *** = p#0.001.
doi:10.1371/journal.pone.0057329.g005
Klf4 Regulates EMT
PLOS ONE | www.plosone.org 10 February 2013 | Volume 8 | Issue 2 | e57329
Figure 6. Klf4 directly regulates the expression of crucial EMT genes. (A) Venn-diagrams depicting the commonly regulated genes between
the data obtained by Klf4 chromatin immunoprecipitation-deep sequencing (ChIP-Seq), gene expression profiling of TGFb-induced EMT (EMT Up and
Dn, respectively), and gene expression profiling of siRNA-mediated Klf4 depletion in the presence of TGFb for 2 days (Klf4 Up and Dn, respectively), all
performed in NMuMG cells. The numbers of genes directly up-regulated (left diagram; 30 genes) or down-regulated (right diagram; 56) during EMT
are shown (see Table S1 for the gene names). (B) Chromatin immunoprecipitation with antibody against Klf4 followed by quantitative PCR (ChIP-
qPCR) to demonstrate the occupancy of Klf4 at the promoters of the N-cadherin (Cdh2), vimentin (Vim) and b-catenin (Ctnnb1) genes. The qPCR data
were normalized to ChIP-qPCR of an intergenic region. (C) Wiggle-tracks to show the binding of Klf4 at the promoters of the N-cadherin (Cdh2),
vimentin (Vim), b-catenin (Ctnnb1), Jnk1 (Mapk8), vascular endothelial growth factor A (Vegfa) and endothelin1 (Edn1) genes by using UCSC genome
browser. These files were generated from Klf4 ChIP-Seq data of NMuMG cells. Statistical values were calculated using an unpaired/paired, two-tailed t-
test and experiments were performed at least three times. * = p#0.05; ** = p#0.01.
doi:10.1371/journal.pone.0057329.g006
Klf4 Regulates EMT
PLOS ONE | www.plosone.org 11 February 2013 | Volume 8 | Issue 2 | e57329
Figure 7. Klf4 directly represses Jnk1 (Mapk8) gene expression, and Jnk1 is required for TGFb-induced EMT and loss of Klf4-induced
cell migration and apoptosis in NMuMG cells. (A) siRNA-mediated depletion of Klf4 expression increases Jnk1 expression as determined by
quantitative RT-PCR. NMuMG cells were treated or not with TGFb for 2 days. (B) Ablation of Klf4 function induces Jnk1 expression. Immunoblotting
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and retroviral production have been previously described [8,46].
After viral production, viral supernatant was filtered (0.46 mm) and
target cells were transduced. Infected cells were positively selected
using puromycin (5 ug/ml).
Scratch Wound Closure Assay
In vitro wound healing assays were performed on confluent cells
transfected with siControl (Stealth RNAiTM siRNA Negative
Controls, 12935-100, Invitrogen), siKlf4 (SASI_Mm01_00114982
and SASI_Mm01_00114983, Sigma), siJnk1 (SA-
SI_Mm01_00163536 & SASI_Mm01_00163537, Sigma) and
siKlf4+ siJnk1 as previously described [47]. Briefly, the media of
the confluent cells was replaced with DMEM containing 2% fetal
bovine serum media and an area was scraped off using a 200 ml
pipette tip. Light microscopic images were taken at time 0 and at
19 hours and the derived data was further analyzed using ImageJ
software to quantify closed area after 19 hours compared to 0
hour.
Migration Assay
Cell migration was assessed in shControl (Mission Non-target
shRNA control vector, SHC002, Sigma) and shKlf4 (SHCLNG-
NM_010637 Mouse, TRCN0000095370; TRCN0000095371 and
TRCN0000095372, Sigma) as described previously [9]. Pictures of
the membrane were taken at a 106 magnification using a
fluorescent microscope (Nikon Diaphot 300). Quantification was
done using ImageJ software.
Apoptosis Assay (Annexin V Assay)
Annexin V antibody was purchased from BD Biosciences
(559934) and staining was performed according to manufacturer’s
instruction. Stained cells were filtered through 40 mm mesh and
analyzed on a FACSCanto II using DIVA software.
Quantitative RT-PCR
Total RNA isolation, cDNA synthesis and quantitative RT-
PCR were performed as described previously [9]. Primer
sequences are available upon request.
Immunoblotting
Immunoblotting was performed as described previously [9]
using following antibodies: Klf4 (09–821, Millipore), E-Cadherin
(610182, Transduction Laboratories), N-Cadherin (M142, Ta-
kara), ZO-1 (617300, Zymed), Fibronectin (F-3648, Sigma), ZO-1
(617300, Zymed), Vimentin (V2258, Sigma), Vinculin (SC-7649,
Santa Cruz Biotechnology), Jnk1/3 (SC-474, Santa Cruz),
GAPDH (G8795, Sigma or ab9485, Abcam for E9 and Py2T
lysates, respectively) and Actin (SC-1616, Santa Cruz).
Immunofluorescence
Cells were plated on coverslips and treated with TGFb for the
times indicated. Immunofluorescence was performed as described
before [9] using following antibodies: E-Cadherin (13–1900,
Zymed), N-Cadherin (610921, Transduction Laboratories), Fibro-
nectin (F-3648), ZO-1 (617300, Zymed), Phalloidin-568 (A12380,
Invitrogen), Paxillin (13520, Transduction Laboratories), Vimen-
tin (V2258, Sigma) and anti-Myc-tag (a gift by M. Cabrita). The
coverslips were counterstained with DAPI (D9542, Sigma) and
imaged with a Zeiss Meta 510 confocal microscope.
Tumor Transplantations
16106 Myc-Klf4-ERTM and firefly luciferase-expressing Py2T
cells in 100 ml of PBS were injected orthotopically into the
mammary fat pad of 7 weeks old female Balb/c nude mice. Mice
were kept on either normal food or Tamoxifen food (TD.55125,
Harlan Laboratories, Inc.). After 27 days of treatment, mice were
sacrificed, and primary tumors, lungs and livers were isolated.
Luciferase levels were measured in lysates prepared from lungs
and liver to to detect metastasis and to calculate the metastatic
index by dividing the average luciferase levels in each organ with
average tumor weights in the mice. All experimental procedures
involving mice were performed according to the guidelines of the
Swiss Federal Veterinary Office (SFVO) and the regulations of the
Cantonal Veterinary Office of Basel Stadt.
Histological Analysis
Paraffin and OCT sections were prepared as described
previously [9]. Tumor cell proliferation and apoptosis was
determined by staining frozen tumor sections for cleaved
caspase-3 (9664, Cell Signaling) and for phospho-Histone 3 (06–
570, Upstate), respectively. Subsequent quantification was per-
formed using Image J software, and the results are displayed as
percentage of the area of positively stained cells compared to the
total tumor area in the microscopic field.
Microarray Processing and Data Analysis
The manufacturer’s protocols for the GeneChip platform by
Affymetrix were followed for microarray experiment in siControl
and siKlf4 transfected NMuMG cells in the absence and presence
of TGFb. Raw microarray data were normalized with Robust
Multi-Array (RMA) and analyzed using X-RayProj Software.
analysis of the expression of Jnk1 during TGFb-induced EMT in NMuMG cells transfected with control siRNA (siControl) or with siRNA against Klf4
(siKlf4). Immunoblotting for actin was used as loading control. (C) Klf4 directly binds the Jnk1 (Mapk8) gene promoter in NMuMG cells as determined
by ChIP using an antibody against Klf4 followed by qPCR using primers specific for the promoter region of the Jnk1 (Mapk8) gene. The qPCR data
were normalized to ChIP-qPCR of an intergenic region. (D) An AP1 activity reporter assay was performed to assess Jnk1/AP-1-mediated transcriptional
activity after Klf4 depletion (siKlf4) in NMuMG cells with or without TGFb for 2 days. Firefly luciferase activity was normalized to co-transfected Renilla
luciferase activity (relative luminescence). (E) Ablation of Jnk1 expression prevents EMT. Phase contrast microscopy of NMuMG cells transfected with
control siRNA (siControl) and siRNA against Jnk1 (siJnk1) before and after TGFb treatment for 2 days. Size bar, 100 mm. (F) Jnk1 depletion represses
EMT. Immunoblotting analysis of the expression levels of Jnk1, the epithelial markers E-cadherin (the correct band is marked with an asterisk) and ZO-
1 and the mesenchymal marker N-cadherin in NMuMG cells treated with either control (siControl) or Jnk1-specific siRNA (siJnk1) during TGFb-induced
EMT. Immunoblotting for Jnk1 was used to assess the siRNA-mediated knock-down efficiency, and immunblotting for actin was used as a loading
control. (G) Down-regulation of Jnk1 expression prevents EMT. The localization and expression levels of EMT markers as indicated was assessed by
immunofluorescence microscopy after 7 days of TGFb treatment in siControl and siJnk1-transfected NMuMG cells. Size bar, 50 mm. (H) Jnk1 is
required for cell migration of NMuMG cells induced by the loss of Klf4 expression, as determined by scratch wound closure assays of control
(siControl), Klf4-depleted (siKlf4), Jnk1-depleted (siJnk1), or siKlf4 and siJnk1 double-depleted (siKlf4+siJnk1) NMuMG cells. (I) Jnk1 is required for
apoptosis of NMuMG cells induced by the loss of Klf4 expression and TGFb treatment for 2 days, as determined by Annexin V staining and flow
cytometry of control (siControl), Klf4-depleted (siKlf4), Jnk1-depleted (siJnk1), or siKlf4 and siJnk1 double-depleted (siKlf4+siJnk1) NMuMG cells.
Statistical values were calculated using an unpaired/paired, two-tailed t-test and experiments were performed at least three times. * = p#0.05;
** = p#0.01; *** = p#0.001.
doi:10.1371/journal.pone.0057329.g007
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One-way analysis of variance (ANOVA) and asymptotic analysis
were used to identify significantly differentially expressed genes.
The microarray data has been deposited on ArrayExpress
platform under the accession number xxxx.
Chromatin Immunoprecipitation
ChIP experiments were performed as previously described
[8,48], starting with 70 mg of chromatin and 5 mg of anti-Klf4 (SC-
20691, Santa Cruz). Quantitative PCR after ChIP was performed
using SYBR Green, using 1/40 of the ChIP sample or a 1:100
dilution of input DNA per PCR reaction. Primer sequences are
available upon request.
ChIP-Seq Data Analysis
The ChIP libraries were prepared with the Illumina ChIP-Seq
DNA Sample Prep Kit (Cat# IP-102–1001) according to
Illumina’s instructions and sequenced on the Genome Analyzer
2 following the manufacturer’s protocols. Subsequent analysis was
performed as described previously [49].
Kaplan-Meier Survival Analysis
Kaplan-Meier survival analysis was performed on patients from
the Uppsala and TRANSBIG cohorts [30,31]. Based on the
median expression of Klf4 (probeset 221841_s_at on HGU133A
Affymetrix chip), the tumors of the Uppsala and TRANSBIG
cohorts were divided into a high and a low Klf4 group. Kaplan-
Meier survival analysis and Cox proportional hazards regression
modeling was performed with the survival package 2.36–5 of R
version 2.11.1 (www.r-project.org). The p-value of the likelihood-
ratio test was calculated between the different groups and
considered statistically significant below 0.05.
AP1 Activity Reporter Assay
NMuMG cells overexpressing the AP1 luciferase reporter
construct (SA Biosciences) were plated in triplicate in a 24 well
plate and reversely transfected with Klf4 siRNAs. One day after
plating, cells were transfected with renilla expressing plasmid.
Fresh growth medium was added after 5 hours of transfection
containing 2 ng/mL TGFb or not. Two days after, cells were
lysed using 16 passive lysis buffer (#E194, Promega), and lysates
were analyzed using the Dual-Luciferase Reporter Assay System
(#E1960, Promega) and a Berthold Luminometer LB960.
Statistical Analysis
Statistical analysis and graphs were generated using the
GraphPad Prism software (GraphPad Software Inc, San Diego,
CA). All statistical analysis was done by unpaired/paired, two-
sided t-test.
Ethics Statement
Animal experiments were performed in strict accordance with
the guidelines of the Swiss Federal Veterinary Office (SFVO) and
the regulations of the Cantonal Veterinary Office of Basel-Stadt
(license numbers 1878, 1907, and 1908). During the whole course
of animal experiments, all efforts were made to minimize suffering.
Supporting Information
Figure S1 Klf4 expression is repressed by canonical
TGFb signaling during TGFb-induced EMT in NMuMG
cells. (A) Morphological changes observed in NMuMG cells
treated with TGFb for 0, 1, 4, 7, 10 and 20 days by using phase-
contrast microscopy. Scale bar, 100 mm. (B) Klf4 protein
expression is reduced during TGFb-induced EMT in NMuMG
and Py2T cells. Expression of the epithelial marker E-cadherin
and the mesenchymal marker fibronectin as well as Klf4 during a
time course of TGFb-treatment was determined by immunoblot-
ting and GAPDH was used as loading control. (C) TGFb-induced
repression of Klf4 expression is dependent on Smad4-mediated
TGFb signaling. Quantitative RT-PCR was performed to monitor
the expression levels of Klf4 during TGFb-mediated EMT in
NMuMG cells expressing a control shRNA (shControl) or an
shRNA against Smad4 (shSmad4). This experiment was only
performed once, hence there is no statistical analysis. (D–E) Klf4
mRNA levels were quantified by quantitative RT-PCR after
treating NMuMG (D) and Py2T (E) cells with TGFbR inhibitor
(TGFbRi), Wnt signaling activator LiCl, EGFR signaling inhibitor
(EGFRi) and DMSO (control) in the absence and presence of
TGFb (2 days). Statistical values were calculated using an
unpaired/paired, two-tailed t-test and experiments were per-
formed at least three times. * = p#0.05; *** = p#0.001.
(TIF)
Figure S2 Klf4 depletion accelerates TGFb-induced
EMT in Py2T murine breast cancer cells. (A) Levels of
Klf4 protein were determined by immunoblotting in NMuMG
and Py2T cells after treatment with Klf4 siRNAs in the absence
and presence of TGFb. The correct band is marked by *Klf4. (B)
Phase contrast microscopy analysis reveals an acceleration of the
morphological changes associated with TGFb-induced EMT in
Klf4-depleted Py2T cells as compared to control siRNA-
transfected cells. Size bar, 100 mm. (C) Py2T cells were either
transfected with control siRNA (siControl) or siRNA against Klf4
(siKlf4). Immunoblotting analysis for the epithelial protein E-
cadherin (the correct band is marked with an asterisk) and the
mesenchymal proteins N-cadherin and fibronectin reveals an
acceleration of TGFb-induced EMT in Py2T cells after ablation of
Klf4 function. Immunoblotting for actin was used as a loading
control. (D) Quantitative RT-PCR was performed to measure the
expression levels of epithelial marker E-Cadherin (Ecad) and
mesenchymal markers N-Cadherin (N-Cad) and fibronectin (Fn1)
as well as Klf4 during TGFb-induced EMT in Py2T cells after
Klf4 ablation. Statistical values were calculated using an
unpaired/paired, two-tailed t-test and experiments were per-
formed at least three times. * = p#0.05; ** = p#0.01;
*** = p#0.001.
(TIF)
Figure S3 Klf4 prevents cell migration and promotes
cell survival during TGFb-induced EMT in Py2T cells.
(A, B) Scratch wound healing assays were performed in NMuMG
cells transiently (A) or stably (B) depleted with Klf4 (siKlf4 or
shKlf4) and images were captured by phase contrast microscope at
0 hour and at 19 hours after creation of the scratch wounds.
Quantification of these experiments are shown in Figure 3A–B. (C)
siRNA-mediated ablation of Klf4 results in an increase in Py2T
cell migration in a trans-well migration assay. siControl and siKlf4
transfected Py2T cells were treated with TGFb for 15 days, and
20% FBS was used as chemo-attractant. (D) Py2T cells transfected
with either control siRNA (siControl) or with siRNA against Klf4
(siKlf4) were treated with TGFb for the days indicated, and the
rates of apoptosis were determined by Annexin-V staining and
flow cytometry analysis. (E) Py2T cells transfected with either
control siRNA (siControl) or with siRNA against Klf4 (siKlf4) were
treated with TGFb for the days indicated. Cells were stained with
propidium iodide (PI), and the percentages of cells in G0/G1 and
S-G2/M phases of the cell cycle were determined by flow
cytometry. Statistical values were calculated using an unpaired/
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paired, two-tailed t-test and experiments were performed at least
three times. * = p#0.05; *** = p#0.001.
(TIF)
Figure S4 Klf4 maintains epithelial differentiation and
prevents EMT in Py2T cells. (A) Induction of Klf4
transcriptional activity by treatment of Myc-Klf4-ERTM-express-
ing Py2T cells with 4-OHT (+OHT) represses the morphological
changes occurring during EMT in control-treated cells (2OHT).
Shown are phase contrast images of Myc-Klf4-ERTM expressing
Py2T cells treated with TGFb for 0, 1, 4 and 7 days in the absence
or presence of 4-OHT. Size bar, 100 mm. (B) Immunoblotting
analysis of the expression of the epithelial marker E-cadherin (the
correct band is marked with an asterisk) and the mesenchymal
markers N-cadherin and fibronectin during TGFb-induced EMT
in Myc-Klf4-ERTM-expressing Py2T cells in which Klf4 tran-
scriptional activity has been induced (+OHT) or not (2OHT).
Activation of Klf4 in Klf4-ER (+OHT) cells results in the
maintenance of the expression of epithelial markers and the
failure to express mesenchymal markers. Actin was used as loading
control.
(TIF)
Figure S5 High Klf4 expression correlates with good
survival prognosis of breast cancer patients and blocks
and metastasis. (A, B) Kaplan-Meier survival analysis reveals a
significant correlation of low Klf4 expression levels and poor
overall disease-free survival in lymph node-negative (LN2; panel
A) and estrogen receptor-negative (ER2; panel B) breast cancer
patients (Uppsala database). (C) Nuclear localization of Myc-Klf4-
ERTM was assessed by immunofluorescence analysis with anti-
Myc antibody in non-induced (2OHT) and induced (+OHT)
Myc-Klf4-ERTM-expressing Py2T cells. Size bar, 50 mm. (D)
Immunofluorescence analysis was performed to assess the
expression levels of the epithelial marker E-cadherin and the
mesenchymal markers N-cadherin and fibronectin in tumors
derived from normal and Tamoxifen-fed mice after Klf4-ER cells
injection in the fat pad of nude mice. (E) Myc-Klf4-ERTM and
firefly luciferase-expressing Py2T cells were orthotopically trans-
planted into the mammary fat pad of immune-compromised Balb/
c nude mice. Mice were treated with normal food or with food
containing Tamoxifen to induce Klf4 transcriptional activity. The
percentages of proliferating tumor cells were quantified by
immunostaining of histological tumor sections with antibody
against phosphorylated histone 3 (pH3). Activation of Klf4 by
Tamoxifen had only a moderate effect on tumor cell proliferation.
(F) Metastatic spread was determined in the tumor-transplanted
mice described in (E) by measuring luciferase activity in extracts of
lungs and livers of the transplanted mice. Activation of Klf4 by
Tamoxifen represses metastatic spread of the transplanted tumor
cells. Statistical values were calculated using an unpaired/paired,
two-tailed t-test. * = p#0.05; ** = p#0.01.
(TIF)
Figure S6 Klf4 directly binds the promoters of key EMT
genes. (A–D) Shown are Venn-diagrams of comparisons between
ChIP-seq data after performing Klf4 ChIP (ChIP-Seq), gene
expression profiling data from Klf4 knockdown (KD) cells in the
absence and presence of TGFb (2 days), and gene expression
profiling data during TGFb-induced EMT (days 0, 1, 4, 7 and 10).
The gene lists originating from a comparison between control and
Klf4 knockdown cells, both in the presence and absence of TGFb,
were merged into lists of genes up-regulated (Up) and down-
regulated (Dn), respectively, by the loss of Klf4 function. Panels (A)
and (B) comprise the genes which were up-regulated during EMT
and upon depletion of Klf4 function. Panels (C) and (D) comprise
the genes down-regulated during EMT and Klf4 depletion. All
experiments were carried out in NMuMG cells. (E) Chromatin
immunoprecipitation with antibody against Klf4 followed by
quantitative PCR (ChIP-qPCR) were performed to demonstrate
the occupancy of Klf4 at the promoters of the N-cadherin (Cdh2),
vimentin (Vim) and b-catenin (Ctnnb1) genes in Py2T cells. The
qPCR data were normalized to ChIP-qPCR of an intergenic
region supposed to be free of transcription factor binding.
Statistical values were calculated using an unpaired/paired, two-
tailed t-test and experiments were performed at least three times.
* = p#0.05.
(TIF)
Figure S7 Klf4 directly represses Mapk8 (Jnk1) gene
expression in Py2T and NMuMG cells and co-depletion of
Klf4 and Jnk1 prevents EMT. (A) Ablation of Klf4 function
induces Jnk1 expression. Immunoblotting analysis of the expression
of Jnk1 during TGFb-induced EMT in Py2T cells transfected with
control siRNA (siControl) or with siRNA against Klf4 (siKlf4).
Immunoblotting for actin was used as loading control. (B, C)
Activation of Klf4 transcriptional activity represses Jnk1 expression.
Immunoblotting analysis of Jnk1 expression upon activation of Klf4
by 4-OHT (+OHT) in control NMuMG cells or inMyc-Klf4-ERTM-
expressing NMuMG cells (B) and in Myc-Klf4-ERTM-expressing
Py2T (C) cells after treatment with TGFb for the days indicated.
Immunoblotting for actin was used as loading control. (D) Klf4
directly binds the Mapk8 (Jnk1) gene promoter in Py2T cells as
determined by ChIP using an antibody against Klf4 followed by
qPCR with primers specific for the promoter region of the Mapk8
(Jnk1) gene. The qPCR data were normalized to ChIP-qPCR of an
intergenic region. (E) Quantitative RT-PCR to assess the knockdown
efficiency of siRNA against Jnk1 in NMuMG cells transfected with
siControl or siKlf4 in the absence and in the presence of TGFb for 2
days. (F) Immunofluorescence microscopy analysis of changes in the
localization and expression levels of EMT markers upon depletion of
both Klf4 and Jnk1. NMuMG cells transfected with either control
siRNA (siControl) or with a combination of siRNAs against Klf4 and
Jnk1 (siKlf4+siJnk1) were left untreated or treated with TGFb for 2
days and stained with antibodies against the epithelial markers E-
cadherin and ZO-1, against the mesenchymal markers N-cadherin
and fibronectin, against paxillin to detect focal adhesion plaques, and
with phalloidin to visualize the actin cytoskeleton. Size bar, 50 mm.
Statistical values were calculated using an unpaired/paired, two-
tailed t-test and experiments were performed at least three times.
**=p#0.01; ***=p#0.001.
(TIF)
Figure S8 Snail1 and Twist1 are regulated by Klf4
during EMT. (A, B) Snail1 (A) and Twist1 (B) mRNA levels
were quantified by quantitative RT-PCR after transient depletion
of Klf4 in NMuMG cells. Cells were either not treated (day 0) or
treated with TGFb for 2 days (day 2). Shown are the fold-changes
as compared to day 0 (no TGFb). Statistical values were calculated
using an unpaired/paired, two-tailed t-test and experiments were
performed at least three times. * = p#0.05.
(TIF)
Figure S9 Working model of Klf4 function during EMT.
Klf4 maintains the epithelial differentiation status by activating the
expression of epithelial genes, such as E-cadherin, and by
repressing the expression of mesenchymal genes, such as Mapk8
(Jnk1), N-cadherin, vimentin, and b-catenin. Upon TGFb-induced
Smad4-dependent repression of Klf4 expression, epithelial genes
are no more activated by Klf4 and mesenchymal genes are de-
repressed, together leading to EMT.
(TIF)
Klf4 Regulates EMT
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Table S1 The table represents a list of genes that are
directly bound by Klf4 and that are either up-regulated
or down-regulated in their expression by the loss of Klf4
function and during the various stages of TGFb-induced
EMT in NMuMG cell.
(JPG)
Table S2 Gene-Ontology analysis reveals that crucial
EMT relevant pathways are under control of Klf4.
GeneGo software was used to categorize the genes into functional
groups. Gene ontology has been performed on direct KLf4 target
genes that are transcriptionally up or down-regulated during
EMT.
(XLSX)
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